Repros Therapeutics Inc. (RPRX) Shares Down 5.2%
Repros Therapeutics Inc. (NASDAQ:RPRX)’s share price fell 5.2% during mid-day trading on Monday . The company traded as low as $1.90 and last traded at $2.01, with a volume of 499,433 shares. The stock had previously closed at $2.12.
Separately, Zacks Investment Research downgraded Repros Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 13th. One research analyst has rated the stock with a sell rating and four have issued a hold rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $21.50.
The firm has a 50 day moving average price of $1.71 and a 200 day moving average price of $1.53. The firm’s market capitalization is $50.10 million.
Repros Therapeutics (NASDAQ:RPRX) last announced its earnings results on Tuesday, May 10th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. Analysts anticipate that Repros Therapeutics Inc. will post ($0.75) EPS for the current year.
Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include Androxal and Proellex. The Company’s primary product candidate Androxal is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound, which is developed for the treatment of secondary hypogonadism in overweight men.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.